Two compounds sit under this goal and they are different kinds of molecule entirely. MOTS-c is a peptide with an interesting mechanism and no human efficacy data. NAD+ is a coenzyme with a real human trial literature whose results are more mixed than the category’s marketing suggests. Batch certificates are published at /coa.
Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21(3):443–454. PMID 25738459; Mitochondria-derived peptide MOTS-c: effects and mechanisms. PMC9854231; Effects of NMN on glucose and lipid metabolism: systematic review and meta-analysis of RCTs. PMID 39531138; Safety and metabolism of long-term NIAGEN (nicotinamide riboside chloride). PMC6611812
”Energy” is the vaguest goal on the site
Cellular energy metabolism and the subjective sense of having energy are not the same thing, and no trial cited on this page measured the second. When you read “energy” in this category it means ATP production, mitochondrial function and metabolic signalling — biochemistry, not how you feel at 3pm.
That is worth stating plainly because the slippage between the two meanings is where most of the category’s marketing lives.
MOTS-c: genuinely novel, entirely preclinical
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA — mitochondrial DNA, not nuclear. That is unusual and it is why the 2015 paper drew attention: it suggested mitochondria act as a signalling origin rather than only as an energy-producing organelle (see our MOTS-c overview).
The described mechanism is inhibition of the folate cycle and its tethered de novo purine biosynthesis, producing a large increase in endogenous AICAR — reported as greater than twenty-fold — which activates AMPK, a central metabolic sensor.
In mice, treatment prevented age-dependent and high-fat-diet-induced insulin resistance and prevented diet-induced obesity.
Every one of those findings is cell culture or rodent. No published human efficacy trial exists. No established human dose, no human safety dataset, no clinical outcome data of any kind. The gap between “prevented diet-induced obesity in mice” and any statement about a person is the whole distance between preclinical and clinical evidence.
NAD+ is not a peptide
Nicotinamide adenine dinucleotide is a coenzyme in cellular energy metabolism (see our NAD+ page). It participates in redox reactions rather than binding a receptor and issuing an instruction, so the receptor-selectivity frame that explains almost everything else in this catalogue does not apply to it.
Its human trial literature is mostly about the oral precursors — NMN and nicotinamide riboside — rather than NAD+ itself, because NAD+ is comparatively large and poorly absorbed orally, which is why it is presented as injectable or intravenous.
Those trials are clear on one point and equivocal on another:
- The biomarker moves. NR and NMN supplementation produced dose-dependent increases in cellular NAD+ in rodents and humans. A first human trial with NR showed a single dose raised blood NAD+ over 24 hours.
- The outcomes are inconsistent. A meta-analysis of NMN randomised controlled trials found no significant benefit on fasting glucose, fasting insulin, glycated haemoglobin or lipid profile across 250–2000 mg/day. A separate systematic review reported improvements in physical performance measures such as six-minute walk distance.
“Raises NAD+” is well supported. “Therefore improves energy” is the step the evidence does not carry uniformly — the same caveat applies under longevity, where NAD+ is also listed.
A note on how popular this compound looks
The abbreviation “NAD” is heavily overloaded — it matches unrelated medical usage, so raw search interest substantially overstates interest in the compound. On our own demand analysis, filtering to genuine NAD+ intent cut the figure by more than an order of magnitude. Treat claims about how researched or popular NAD+ is with that in mind.
What we can evidence
Identity, content, purity, sterility and batch traceability, third-party tested per lot with the certificate reachable from the QR code on the pen. Neither compound holds a marketing authorisation; the oral precursors are generally sold as food supplements, which is a third regulatory framework again.
Further reading: mitochondrial peptides, MOTS-c vs NAD+, NAD+ vs NMN.
